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Hepatic glucose production (HGP) is crucial for
glucose homeostasis, but the underlying mecha-
nisms have not been fully elucidated. Here, we
show that a calcium-sensing enzyme, CaMKII, is
activated in a calcium- and IP3R-dependent manner
by cAMP and glucagon in primary hepatocytes and
by glucagon and fasting in vivo. Genetic deficiency
or inhibition of CaMKII blocks nuclear translocation
of FoxO1 by affecting its phosphorylation, impairs
fasting- and glucagon/cAMP-induced glycogenol-
ysis and gluconeogenesis, and lowers blood glucose
levels, while constitutively active CaMKII has the
opposite effects. Importantly, the suppressive effect
of CaMKII deficiency on glucose metabolism is abro-
gated by transduction with constitutively nuclear
FoxO1, indicating that the effect of CaMKII defi-
ciency requires nuclear exclusion of FoxO1. This
same pathway is also involved in excessive HGP in
the setting of obesity. These results reveal a
calcium-mediated signaling pathway involved in
FoxO1 nuclear localization and hepatic glucose
homeostasis.
INTRODUCTION
Liver is the main organ responsible for maintaining euglycemia
under conditions of nutrient deprivation. During the early stages
of fasting, liver uses glycogen stores to mobilize glucose (Rad-
ziuk and Pye, 2001). As fasting progresses, de novo synthesis
of glucose from noncarbohydrate precursors, gluconeogenesis,
becomes the main contributor to hepatic glucose production
(HGP) (Lin and Accili, 2011). These changes occur rapidly in
response to direct hormonal signaling. In addition, both insulinCand glucagon affect transcription of glucose-6-phosphatase
(G6pc), which is involved in both gluconeogenesis and glyco-
genolysis, and phosphoenolpyruvate carboxykinase (Pck1),
which also regulates HGP (Pilkis and Granner, 1992; Burgess
et al., 2007). During fasting, changes in the subcellular localiza-
tion of ‘‘glucogenic’’ transcription factors, such as FoxO (1, 3,
and 4) and Crtc2, activate expression of these genes (Lin and
Accili, 2011). In addition, different coactivators, such as peroxi-
some proliferator-activated receptor-g coactivator-1a (PGC-1a)
and CBP, are thought to interact with components of the cAMP
response, including CREB, hepatic nuclear factor 4a (HNF4a),
Sirt1, and Clock genes, leading to an increase in transcription
of gluconeogenic genes (Hall et al., 1995; Matsumoto et al.,
2007; Puigserver et al., 2003; Rhee et al., 2003). In addition to
its role in stimulating HGP during fasting, excessive glucagon
signaling is thought to play an important role in hyperglycemia
in type 2 diabetes (Sørensen et al., 2006; Unger and Cherrington,
2012; Saltiel, 2001).
The intracellular signal transduction pathways through which
glucagon stimulates the nuclear translocation of HGP transcrip-
tion factors in general, and FoxO1 in particular, to stimulate HGP
is not well understood. In this context, we became interested in
previous reports that linked intracellular calcium (Ca2+i) to the
regulation of gluconeogenesis (Friedmann and Rasmussen,
1970; Kraus-Friedmann and Feng, 1996; Marques-da-Silva
et al., 1997). For example, glucagon and cAMP can increase
Ca2+i, and Ca
2+
i chelation has been shown to reduce glucagon
induced HGP gene expression and glucose production (Bygrave
and Benedetti, 1993; Staddon and Hansford, 1989; Mine et al.,
1993). Based on these previous studies, which did not offer
a molecular mechanism linking Ca2+i to hepatic glucose metab-
olism, we conceived a hypothesis implicating a role for the
Ca2+i -sensing enzyme CaMKII.
Calcium calmodulin-dependent kinase II (CaMKII) is a serine-
threonine kinase that is an important mediator of Ca2+i signaling
in cells (Couchonnal and Anderson, 2008; Singer, 2011). There
are four CaMKII isoforms—a, b, g, and d—each encoded by a
separate gene. The a and b isoforms are mostly neuronal,ell Metabolism 15, 739–751, May 2, 2012 ª2012 Elsevier Inc. 739
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CaMKII in Hepatic Glucose Productionwhereas CaMKIIg and d are expressed in a wide variety of
tissues. After binding calcium/calmodulin complex, autophos-
phorylation on Thr287 results in calcium/calmodulin indepen-
dent activity (Couchonnal and Anderson, 2008; Singer, 2011).
Most studies on CaMKII have been carried out in neurons and
cardiomyocytes, and there is only a limited understanding of
CaMKII in other tissues, with none to date related to hepatic
glucose metabolism. In the present study, we show that CaMKII
activity is increased by cAMP and glucagon and also in response
to fasting in vivo. We further demonstrate that CaMKII plays an
essential role in the regulation of glycogenolysis and gluconeo-
genesis. In particular, we provide evidence that CaMKII has
a profound effect on FoxO1 nuclear localization in a manner
that regulates the expression of two key enzymes, G6pc and
Pck1, in vitro and in vivo. Finally, we present evidence suggest-
ing that this same pathway is involved in excessive HGP in the
setting of obesity.
RESULTS
Glucagon and Fasting Activate Hepatic CaMKII
in an IP3R- and Ca2+i-Dependent Manner
Glucagon has been shown to increase intracellular calcium
(Ca2+i) in hepatocytes (HCs) (Staddon and Hansford, 1989),
which we recently verified (Wang et al., 2012). To determine
whether glucagon activates the Ca2+i-sensing enzyme, CaMKII,
we treated primarymurine HCswith glucagon for various periods
of time and then assayed CaMKII enzymatic activity and CaMKII
phosphorylation at Thr287, which is a measure of its activation
state (Couchonnal and Anderson, 2008; Singer, 2011). The
results of both assays show that CaMKII activity increases as
a function of time of glucagon treatment (Figures 1A and 1B).
We used the cytosolic calcium chelator,1,2-bis[2-aminophe-
noxy]ethane-N,N,N 0,N0-tetraacetic acid tetrakis [acetoxymethyl
ester] (BAPTA-AM), to determine the role of Ca2+i on CaMKII
activation and found that BAPTA-AM markedly decreased
glucagon-induced CaMKII phosphorylation (Figure 1C).
Inositol 1,4,5-trisphosphate receptor (IP3R) channels, located
in the endoplasmic reticulum (ER), release Ca2+ in response to
IP3 binding and play a major role in intracellular Ca
2+
i homeo-
stasis. Additional studies have revealed that glucagon-induced
PKA phosphorylates and increases IP3R activity, leading to
an increase in Ca2+i (Wang et al., 2012). Glucagon has also
been shown to induce phospholipase C-mediated IP3 release
(Hansen et al., 1998). To investigate the contribution of IP3Rs
in glucagon-induced CaMKII activation, we used the IP3R
inhibitor xestospongin C and, as a complementary approach,
adeno-Cre-treated HCs from Ip3r1fl/fl mice. Both xestospongin
C treatment and Cre-mediated deletion of IP3R1 led to a signifi-
cant decrease in glucagon-induced CaMKII phosphorylation,
demonstrating the critical role of IP3Rs in this process
(Figure 1D).
Glucagon receptor signaling, including that involved in the
increase in Ca2+i (Staddon and Hansford, 1989), is mediated
by activation of adenylate cyclase to produce cAMP, followed
by activation of protein kinase A (PKA), a key enzyme involved
in HGP. In this context, we found that treatment of HCs with
8-bromo-cAMP mimicked the effect of glucagon and led to
a marked increase in phospho-CaMKII (Figure 1E). Moreover,740 Cell Metabolism 15, 739–751, May 2, 2012 ª2012 Elsevier Inc.when HCs were treated with the PKA inhibitor H89 prior to the
addition of glucagon, glucagon-mediated increase in phospho-
CaMKII was markedly inhibited (Figure 1F). These data support
the existence of a pathway in which glucagon-cAMP-PKA
signaling promotes phosphorylation/activation of CaMKII
through its effects on IP3R-mediated intracellular Ca2+ release.
To examine whether CaMKII is regulated by glucagon in vivo,
we challenged mice with a bolus of intraperitoneal (i.p.)
glucagon. Consistent with the effects observed in cultured
HCs, hepatic CaMKII phosphorylation was induced by glucagon
treatment (Figure 1G). We found that a glucagon dose as low as
1 mg kg1 was capable of phosphorylating CaMKII in the liver
(Figure S1A available online). To gain in vivo evidence that
IP3Rs are important in the regulation of glucagon-mediated
CaMKII phosphorylation, we treated mice with i.p. xestospongin
C for 4 days. The mice were then challenged with glucagon, and
liver extracts were assayed for p-CaMKII. As shown in Figure 1H,
xestospongin C treatment markedly reduced glucagon-induced
CaMKII phosphorylation. Next, we compared hepatic CaMKII
phosphorylation during the transition from a fed to fasting state,
which is known to elevate plasma glucagon (Lin and Accili, 2011)
(Figure S1B). The data show that hepatic CaMKII phosphoryla-
tion was significantly increased upon fasting, whereas the total
amount of CaMKII appeared to be unaffected by nutrient status
(Figure 1I). Moreover, upon refeeding, the level of p-CaMKII
in liver diminished (Figure 1J). As with glucagon treatment, fast-
ing-induced phosphorylation of CaMKII was suppressed by
xestospongin C treatment of the mice (Figure S1C). These data
show that activity of hepatic CaMKII is regulated by nutrient
status in a manner that is consistent with a potential role in
fasting-induced HGP.
CaMKII Promotes Glucose Production in Primary HCs
CaMKIIg is the major CaMKII isoform in HCs, and the other iso-
forms are not induced in HCs lacking the g isoform (Figure 2A).
In view of the regulation of hepatic CaMKII activity by glucagon
and fasting in vivo, we assayed glucose production in HCs
from wild-type (WT) and Camk2g/ mice. We examined the
cells under basal conditions and after stimulation with forskolin,
a glucagon mimetic and a potent adenylate cyclase activator
(Harano et al., 1985). The data show that both basal and forsko-
lin-induced glucose production was suppressed in CaMKIIg-
deficient HCs (Figure 2B).We next examined glucose production
in WT HCs transduced with adenoviruses expressing constitu-
tively active CaMKII (adeno-CA-CaMKII), ‘‘kinase-dead’’ domi-
nant-negative CaMKII (adeno-KD-CaMKII) (Pfleiderer et al.,
2004), or LacZ control. CA-CaMKII possesses an amino acid
substitution, T287D, which mimics autophosphorylation at
T287 and results in autonomous activity in the absence of bound
calcium/calmodulin, while KD-CaMKII has a disabling mutation
in the kinase domain (Pfleiderer et al., 2004). We observed an
increase in both basal and forskolin-induced glucose release in
cells transducedwith adeno-CA-CaMKII (Figure 2C; Figure S1D).
HCs transduced with adeno-KD-CaMKII, which resulted in
40% decrease in CaMKII activity (Figure S1E), showed
decreased forskolin-induced glucose production (Figure 2C).
The role of CaMKII on HGP prompted us to investigate tran-
scriptional effects on two genes encoding enzymes that regu-
late HGP, glucose-6-phosphatase and phosphoenolpyruvate
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Figure 1. Glucagon and Fasting Activates Hepatic CaMKII
(A) CaMKII enzyme activity was assayed in triplicate wells of primary mouse HCs stimulated with 100 nM glucagon (Gluc) or vehicle control (Veh) for the indicated
times (*p < 0.05 and **p < 0.01 versus Veh; mean ± SEM).
(B–J) Extracts of HCs or liver were probed for phospho-CaMKII, total CaMKII, and b-actin by immunoblot assay. HCs were incubated with 100 nM glucagon for
the indicated times (B). Glucagon was added to HCs that were pretreated for 1 hr with vehicle control (Veh) or 5 mMBAPTA-AM (C). Glucagon was added to HCs
that were pretreated with 0.5 mM xestospongin (XesC) or to HCs from Ip3r1fl/fl mice transduced with adeno-LacZ control or adeno-Cre (bar graph = Ip3r1mRNA
levels) (D). Glucagon was added to HCs that were pretreated for 1 hr with vehicle control (Veh) or 10 mMH89 (E). HCswere incubated with 100 mM8-bromo-cAMP
for the indicated times (F). In vivo experiments are shown in (G)–(J). In (G), mice were treated for 30 min with 200 mg kg1 body weight of glucagon i.p., and in (H),
micewere pretreated with 10 pmol g1 xestospongin C or vehicle control i.p. 4 days prior to glucagon treatment. In (I) and (J), micewere fed ad libitum or fasted for
12 hr, or fasted for 12 hr and then refed for 4 hr. See also Figure S1 and Table S1.
Cell Metabolism
CaMKII in Hepatic Glucose Productioncarboxykinase. To this end, we assayed G6pc and Pck1 mRNA
levels in the models described above (Figures 2D and 2E). In all
cases, knockout or KD-CaMKII-mediated inhibition of CaMKII
lowered forskolin- or glucagon-induced gene expression,
whereas CA-CaMKII increased gene expression. In the absence
of forskolin or glucagon, expression levels of G6pc and Pck1
mRNA in WT HCs were much lower than those in hormone-
treated WT HCs, but even under these conditions CaMKIIg
deficiency led to a lowering of gene expression (Figure S1F).
Moreover, adeno-KD-CaMKII did not decrease the low but
detectable level of forskolin-inducedG6pcmRNA in HCs lacking
CaMKIIg (Figure S1G), consistent with the premise that the
suppressive effect of KD-CaMKII on G6pc in Figure 2E is due
to CaMKII inhibition.CIn summary, the CaMKII deficiency and inhibition data show
the importance of endogenous CaMKII in glucose production
and Pck1/G6pc gene expression, while the data with CA-CaMKII
show that when the enzyme is expressed at a high level, it can
force these processes in the absence of hormones or increase
them in the presence of hormones.
Hepatic Glucose Production In Vivo Is Impaired by
CaMKIIg Deficiency and Stimulated by Constitutively
Active CaMKII
To assess the functional role of CaMKII in hepatic glucose
metabolism in vivo, we first examined fasting blood glucose
levels in WT and Camk2g/ mice. Consistent with our in vitro
data, we observed amodest but statistically significant decreaseell Metabolism 15, 739–751, May 2, 2012 ª2012 Elsevier Inc. 741
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Figure 2. CaMKII Regulates Glucose Production and Hepatic G6Pc and Pck1 Expression in Primary HCs
(A) RNA from HCs from three WT and three Camk2g/ mice and mouse brain from a WT mouse were probed for the indicated Camk2 isoform mRNAs
by RT-PCR.
(B) HCs fromWT and Camk2g/mice were serum-depleted overnight and then incubated with forskolin (10 mm) for 14 hr in serum- and glucose-free media, and
then glucose in the medium was assayed (**p < 0.01 versus WT in each group; mean ± SEM).
(C) HCs from WT mice were transduced with adenoviral vectors expressing LacZ, CA-CaMKII, or KD-CaMKII at an MOI of 20 and then assayed for glucose
production as in (B) (*p < 0.05 and **p < 0.01 versus LacZ in each group; mean ± SEM).
(D and E) HCs similar to those in (B) and (C) were serum-depleted overnight and then incubated for 5 hr with 10 mM forskolin or 100 nM glucagon in serum-free
media, as indicated. RNA was assayed forG6pc and Pck1mRNA by RT-qPCR (*p < 0.05 and **p < 0.01 versus LacZ orWT in each group; mean ± SEM). See also
Figure S2 and Table S1.
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CaMKII in Hepatic Glucose Productionin blood glucose levels in fasted Camk2g/ versus WT mice
(Figure 3A). The difference in fasting glucose concentration
was not associated with an increase in circulating insulin or a
decrease in glucagon concentrations in knockout versus WT
mice (Figure S2A, left). The mutant mice also showed lower
plasma glucose in response to a pyruvate challenge test (Fig-
ure 3B). Consistent with the primary HC data, there was a
decrease in G6pc and Pck1 mRNA levels in the livers of fasting
Camk2g/ mice (Figure 3C). Similar data were obtained in
mice treated with glucagon (Figure 3D).
Consistent with these data, treatment of C57BL/6 mice with
adeno-KD-CaMKII, which inhibited liver CaMKII activity by
45% (Figure S2B), decreased fasting blood glucose (Figure 3E).
As above, plasma glucagon and insulin were not different
between the control and experimental groups (Figure S2A, right).
In line with blood glucose data, hepatic expression of G6pc and
Pck1 mRNA was lower in mice injected with KD-CaMKII
(Figure 3F). Because CaMKII inhibition lowers the level of the
mRNA for the key glycogenolytic enzyme glucose-6-phospha-742 Cell Metabolism 15, 739–751, May 2, 2012 ª2012 Elsevier Inc.tase, we examined the effect of acute and chronic CaMKII inhi-
bition on liver glycogen content and, as another indicator of
glycogen, the percent of periodic acid-Schiff (PAS)-positive
cells. The data show that adeno-KD-CaMKII or CaMKII gene tar-
geting increases hepatic glycogen in fasting mice (Figure 3G).
We next examined the effect of constitutively active hepatic
CaMKII in mice by treating mice with adeno-CA-CAMKII. The
CA-CaMKII group had elevated blood glucose levels after pyru-
vate challenge, increased liverG6pc and Pck1mRNA levels, and
increased liver glycogen content (Figures S2C–S2E). CA-CaMKII
administration did not alter plasma glucagon or insulin (data not
shown). These combined in vivo data show that CaMKII affects
plasma glucose levels, pyruvate conversion into glucose, and
the expression of hepatic glucose metabolism genes.
CaMKII Promotes Nuclear Localization of FoxO1
A major transcription factor involved in HGP is FoxO1, which is
regulated primarily by changes in its localization between the
cytoplasm and nucleus (Accili and Arden, 2004). We therefore
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Figure 3. CaMKIIg Deficiency or Acute Inhibition In Vivo Decreases Blood Glucose and Hepatic G6pc and Pck1
(A) Blood glucose of 12-hr-fasted 8-week-old WT and Camk2g/ mice (*p < 0.05).
(B) As in (A), but the mice were fasted for 18 hr and then challenged with 2 mg kg1 pyruvate (B) (*p < 0.05; **p < 0.01; ***p < 0.005; mean ± SEM).
(C) Liver G6pc and Pck1 mRNA in 12-hr-fasted WT and Camk2g/ mice (**p < 0.01; ***p < 0.001; mean ± SEM).
(D) WT and Camk2g/mice were injected i.p. with glucagon (200 mg kg1) and sacrificed 30 min later. Liver G6pcmRNA was assayed (*p < 0.05; mean ± SEM).
(E–G) Nine-week-old WT mice were administered 1.5 3 109 pfu of adeno-LacZ or KD-CaMKII, and 5 days later the following parameters were assayed in
12-hr-fasted mice: blood glucose (E, ***p < 0.001; mean ± SEM), liverG6pc and Pck1mRNA (F, **p < 0.01; ***p < 0.001; mean ± SEM), and liver glycogen content
and PAS-positive cells (G, **p < 0.01; mean ± SEM). (G) also shows liver glycogen content in fasted WT and Camk2g/ mice (*p < 0.05; mean ± SEM). For all
panels, n = 5/group except in (D), where n = 4/group.
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CaMKII in Hepatic Glucose Productionassayed the distribution of GFP-tagged FoxO1 that was trans-
duced into HCs isolated from WT versus Camk2g/ mice.
Under serum-starved conditions, the majority of GFP-FoxO1
was in the nucleus in WT HCs, whereas Camk2g/ HCs dis-
played primarily cytosolic localization of GFP-FoxO1 (Figure 4A).
Moreover, when HCs were transduced with adeno-CA-CaMKII,
FoxO1 became predominantly nuclear, while transduction with
adeno-KD-CaMKII caused mostly cytoplasmic FoxO1 (Fig-
ure 4B). We noted that nuclear FoxO1was substantial in cultured
HCs under the ‘‘basal’’ cell culture conditions used here, and
so the fold increase with CA-CaMKII was limited. We therefore
lowered basal nuclear FoxO1 using short incubations with
insulin, which then revealed a marked increase in nuclear
FoxO1 with CA-CaMKII (Figure 4C). Although this experiment
was done using a high level of total CaMKII protein expression
(see Figure S1D), a similar experiment using a lower multiplicityCof infection (MOI) of CA-CaMKII showed an increase in nuclear
FoxO1 at a level of total CaMKII protein thatwas similar to endog-
enous CaMKII (Figure S3A). To show relevance in vivo, we tested
the effect of CaMKIIg deficiency or inhibition in fasting mice.
Nuclear FoxO1 in liver was prominent under fasting conditions
(Figure 4D, top blot), and it was markedly diminished in
Camk2g/ mice or mice transduced with adeno-KD-CaMKII
(Figure 4D, middle two blots). Feeding diminished nuclear
FoxO1, and nuclear FoxO1 was increased under these condi-
tions by bothCA-CaMKII and glucagon (Figure 4D, bottomblots).
cAMP-mediated induction of G6pc mRNA in primary hepato-
cytes is suppressed R50% by Foxo1 shRNA, suggesting an
important role for FoxO1 in the endogenous setting (Matsumoto
et al., 2007). Consistent with these data, we found that induction
of luciferase downstream of the human G6PC promoter was
bluntedwhen three consensus FoxO-binding sites weremutatedell Metabolism 15, 739–751, May 2, 2012 ª2012 Elsevier Inc. 743
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Figure 4. CaMKII Regulates Hepatic FoxO1 Subcellular Localization
(A) HCs fromWT and Camk2g/mice were transduced with an adenovirus expressing murine GFP-FoxO1 at an MOI of 2. Cells were serum-depleted overnight
and then incubated for 5 hr in serum-free media. FoxO1 subcellular localization was assessed by indirect immunofluorescence. Bar, 10 mm. Data are quantified in
the right panel. (#p < 0.0005; mean ± SEM).
(B) HCs were transduced with adenoviral vectors expressing LacZ, CA-CaMKII, or KD-CaMKII at an MOI of 20 and then transduced 4 hr later with adeno-GFP-
FoxO1, followed by fluorescence microscopy and quantification as in (A) (#p < 0.005 versus LacZ; mean ± SEM). Bar, 5 mm.
(C) HCs were transduced with adeno-LacZ or CA-CaMKII and then adeno-GFP-FoxO1 as in (B). After incubation in serum-depleted medium overnight and then
serum-free medium for 5 hr, the cells were treated with 100 nM insulin for the indicated times. FoxO1 subcellular localization was quantified as in (B) (*p < 0.005
versus LacZ in each group; mean ± SEM).
(D) Nuclear FoxO1 and nucleophosmin were probed by immunoblot in livers from fasted WT mice, Camk2g/ mice, or WT mice treated with adeno-LacZ or
KD-CaMKII; from fed WT mice treated with adeno-LacZ or CA-CaMKII; or from fed WT mice treated for 30 min with 200 mg kg1 body weight of glucagon i.p.
For the glucagon experiment, the average FoxO:Np densitometric ratio values are in the graph (*p = 0.029; blemishes in lanes 6 and 8 were excluded from the
densitometry analysis). See also Figure S3 and Table S2.
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CaMKII in Hepatic Glucose Production(Ayala et al., 1999; von Groote-Bidlingmaier et al., 2003) (Fig-
ure S3B). However, this hepatoma cell line—reporter construct
experiment does not distinguish between cAMP and dexameth-
asone effects and may not accurately reflect the endogenous
situation. For example, reporter induction here was much less
robust than actualG6pcmRNA induction in primary hepatocytes
(Matsumoto et al., 2007), and the identified promoter element
may not be the only site required for regulation. Therefore, rather
than pursue this model further as a way to assess the functional
importance of FoxO1 in CaMKII-mediated G6pc expression, we
instead focused on induction of endogenous G6pc in primary
hepatocytes and, most importantly, in vivo. To begin, we
compared the ability of CA-CaMKII to induce G6pc in HCs744 Cell Metabolism 15, 739–751, May 2, 2012 ª2012 Elsevier Inc.from WT versus L-Foxo1 knockout (KO) mice, which lack
FoxO1 in liver (Matsumoto et al., 2007). Consistent with previous
studies (Puigserver et al., 2003; Matsumoto et al., 2007), forsko-
lin-induced expression of G6pc was suppressed in the absence
of FoxO1 (Figure 5A, right graph). Most importantly, the increase
inG6pcmRNA expression by CA-CaMKII was markedly blunted
by FoxO1 deficiency. In the absence of forskolin, gene expres-
sion was much lower as expected (Figure 5A, left graph; note y
axis scale), but even here CA-CaMKII-induced gene expression
was almost completely dependent on FoxO1. Finally, we docu-
mented that the nuclear localization of two other transcription
factors involved in HGP, CREB, and Crtc2, were not decreased
by CaMKII inhibition or deficiency (Figures S3C and S3D). These
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Figure 5. Impairment of Glucose Metabolism by CaMKII Inhibition Is Rescued by Transduction with Constitutively Nuclear FoxO1-ADA
(A) HCs from WT or L-FoxO1 knockout mice were transduced with adeno-LacZ or CA-CaMKII. The cells were serum-depleted overnight and then incubated for
5 hr in the absence or presence of forskolin (10 mm) in serum-free media. RNA was assayed for G6pc mRNA (*p < 0.001; mean ± SEM).
(B) HCs fromWT and Camk2g/mice were administered adeno-LacZ or FoxO1-ADA at anMOI of 0.2. Cells were serum-depleted overnight and then incubated
for 5 hr with 10 mM forskolin in serum-free media. RNA was assayed for G6pc and Pck1 mRNA (**p < 0.01 versus WT groups; #p < 0.05 and ##p < 0.01 versus
Camk2g//LacZ group; mean ± SEM). Inset, the nuclei from a parallel set of cells were probed for FoxO1 and nucleophosmin by immunoblot; the average
densitometric ratio appears below each pair of lanes.
(C–E) Eight-week-old WT mice were administered adeno-LacZ or KD-CaMKII, and then, one day later, half of the adeno-KD-CaMKII mice received
adeno-FoxO1-ADA, while the other half received adeno-LacZ control. Blood glucose levels were assayed at day 5 after a 12-hr fast (*p < 0.05 versus LacZ/LacZ;
#p < 0.05 versus KD/LacZ; n = 5/group; mean ± SEM), and liver was assayed for nuclear FoxO1 protein (**p% 0.01 versus KD/LacZ; mean ± SEM); G6pc, Pck1
and Igfbp1 mRNA (*p < 0.05 and **p < 0.01 versus LacZ/LacZ; #p < 0.05 versus KD/LacZ; n = 3/group; mean ± SEM). The inset in (E) shows the level of
hemagglutinin (HA)-tagged KD-CaMKII protein (anti-HA immunoblot). See also Figure S4.
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promotes FoxO1 nuclear localization, which then leads to induc-
tion of G6pc.
To further validate the importance of FoxO1 in the impairment
of HGP by CaMKII deficiency or inhibition, we transduced HCs
from Camk2g/ mice with adenovirus containing a phosphory-
lation-defective, constitutively nuclear FoxO1 mutant (FoxO1-
ADA) (Nakae et al., 2001). We observed that the suppressive
effect of CaMKIIg deficiency on forskolin-induced G6pc and
Pck1mRNA expression was abrogated by transduction with ad-
eno-FoxO1-ADA (Figure 5B). Note that the level of FoxO1-ADA
used here was low enough so as not to increase G6pc or Pck1
in forskolin-treated WT HCs, and the level of nuclear FoxO1 inCtheCamk2g/ + ADA groupwas similar to the endogenous level
in theWT + LacZ group (inset, Figure 5B). ThePck1 results in Fig-
ure 5B, as well as those in Figures 2 and 3, are interesting in view
of the finding that germline knockdown of FoxO1 does not affect
Pck1 induction (Nakae et al., 2002; Barthel et al., 2001).
However, more acute silencing of FoxO1 does suppress Pck1
(Matsumoto et al., 2007), and so manipulations of CaMKII may
be more parallel to that setting. Consistent with the effect of
FoxO1-ADA on HGP gene expression, treatment of mice with
adeno-FoxO1-ADA adenovirus rescued the impairment of
glucose homeostasis in adeno-KD-CaMKII-treated mice (Fig-
ures 5C–5E). Note that this result cannot be explained by defec-
tive transduction with adeno-KD in the ADA group (inset,ell Metabolism 15, 739–751, May 2, 2012 ª2012 Elsevier Inc. 745
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CaMKII in Hepatic Glucose ProductionFigure 5E). Taken together, these results are consistent with
a model in which CaMKII contributes to HGP through promoting
nuclear localization of FoxO1.
The Role of Non-AKT-Phospho-FoxO1 Sites and p38
MAP Kinase in CaMKIIg-Mediated FoxO1 Nuclear
Localization
Insulin/Akt promotes FoxO1 nuclear exclusion through phos-
phorylation of T24, S253, and S316 (murine residues) (Brunet
et al., 1999). Although CaMKII is a kinase, it could activate
a phosphatase and thereby promote nuclear localization of
FoxO1 by indirectly decreasing the phosphorylation at these
sites. However, we found that phosphorylation at these three
sites was not altered in liver from Camk2g/ mice (Figure S4A).
FoxO1 acetylation, which can also affect FoxO1 localization and
activity in HCs (Accili and Arden, 2004), was also not affected by
CaMKII deficiency (Figure S4B).
FoxO1 can also be phosphorylated at other Ser/Thr residues
by other kinases, such as p38 MAP kinase (Asada et al., 2007),
and these phosphorylation events might promote FoxO1 nuclear
localization, not exclusion. To assess the possible role of CaMKII
in the phosphorylation of non-Akt sites, we used the model dis-
played in Figure 4A, i.e., serum-starvedWT andCamk2g/ (KO)
HCs transduced with GFP-FoxO1, which also carries a FLAG
tag. FoxO1 was immunopurified using anti-FLAG, followed by
reduction, alkylation, and proteolytic digestion using a triple
protease protocol developed by MacCoss et al. (2002). Phos-
phorylated peptides were enriched by TiO2 chromatography
and then analyzed by LC-MS/MS (Cantin et al., 2007) using
MS-based shotgun proteomic methods and label-free quantita-
tion by spectral counting (Cantin et al., 2007). The FoxO1 protein
was identified with 70% sequence coverage, and a total of 57
phosphopeptides for WT and 63 phosphopeptides for KO
samples were identified (Tables S1 and S2). The peptide false
discovery rate (FDR) was less than 1%. Stringent selection
criteria were used so that all identified phosphopeptides would
have high confidence.
These criteria, with further validation using the phosphopep-
tide analysis tools Debunker and Ascore (Lu et al., 2007; Beauso-
leil et al., 2006), enabled the identification of 11 phosphorylation
sites: S284, S295, S326, S467, S475, T24, S246, S253, S413,
S415, and T553 (see Figure S4C for murine FoxO1 sequence).
Figure 6A shows the spectral counts, the Debunker score, and
Ascore of each of these 11 FoxO1 phosphopeptides from the
KO and WT samples. Most phosphorylation sites are well above
the high confidence cutoff values of 0.5 and 12 for Debunker and
Ascore, respectively. Five sites with slightly lower values of
Debunker or A scores were subjected to manual verification,
and their annotated tandem mass spectra are shown in Figures
S5D and S5E for KO peptides 4 and 5 and the aforementioned
website for WT peptides 7, 10, and 11. The characteristic
b- and/or y-ions for the phospho-sites are all identified. The
lower scores are most likely due to the low-abundance fragment
ions or lack of neutral losses of phosphoric acid because of the
nature of the amino acid sequence for these peptides.
The ratio of spectral KO:WT counts, which was calculated only
for peptides with a combined spectral count in KO and WT
samples above 10, was used to obtain a measure of the relative
expression of identified phosphorylated peptides. By this anal-746 Cell Metabolism 15, 739–751, May 2, 2012 ª2012 Elsevier Inc.ysis, only phosphorylation of S295, S467, S475 (peptides 2, 4,
and 5) were significantly lower in the KO based on a cutoff value
of %0.5, with the ratio of spectral counts in KO versus WT of
0.45, 0.38, and 0.5, respectively. Although the peptide contain-
ing p-S246 had a combined spectral count of 7, and thus did
not reach the prespecified criterion of >10, it showed a lower
trend in the KO versus WT (2 versus 5, 0.4). In contrast, S326
(peptide 3) had a ratio of 1.65, indicating upregulation in KO
versus WT.
As an initial test of function for the some of the sites lower in the
KO, we used an available plasmid encoding FoxO1 with S-A
mutations at seven Ser residues (7A-FoxO1), including Ser295
and 475, as well as Ser246 (Asada et al., 2007). When trans-
fected to a similar levels in Foxo1/ HCs, 7A-FoxO1 showed
strikingly less nuclear localization than WT FoxO1 in response
to glucagon, while cytoplasmic FoxO1 was higher in the cells
transfected with the mutant FoxO1 (Figure 6B). We also tested
a construct that had the same seven S-A mutations as in 7A
plus 2 additional S-A mutations in S326 and S467 (mutant 9A)
(Asada et al., 2007). This mutant showed similarly defective
nuclear localization (Figure S4F). Moreover, whereas adeno-
CA-CaMKII transduction increased nuclear WT-FoxO1, consis-
tent with the data in Figure 4D, CA-CaMKII did not increase
nuclear 7A-FoxO1 (Figure 6C). These combined data are consis-
tent with a model in which CaMKII directly or indirectly alters the
phosphorylation of certain Ser residues in FoxO1 in a manner
that promotes its nuclear localization.
Asada et al. (2007) found evidence of FoxO1 phosphorylation
at several sites, including Ser284, 295, 467, and 475, in HEK293T
cells transfected with the upstream p38 kinase MKK6. Because
p38 has been implicated in the stimulation of HGP (Cao et al.,
2005), and CaMKII can activate p38 when studied in neurons
(Blanquet, 2000), we considered the possibility of a CaMKII/
p38 / FoxO1 phosphorylation/nuclear localization pathway
involved in HGP. We first confirmed that p38 was phosphory-
lated, which is a measure of its activation, in the livers of fasting
mice (Figure S5A) and that inhibition of p38 by the high-affinity
competitive inhibitor SB202190 blocked the expression of
G6pc and Pck1 in glucagon-stimulated HCs (Figure S5B, left).
The inhibitor data were confirmed using adeno-Cre-transduced
HCs isolated from the livers of from P38afl/fl mice (Figure S5B,
right). To test a potential link between CaMKII and p38, we
compared serum-starved HCs from WT and Camk2g/ mice
and found a striking decrease in phospho-p38 in the CaMKIIg-
deficient HCs (Figure S5C). We then determined whether p38
was involved in hepatic FoxO1 nuclear localization in vivo by
comparing fasting mice treated with SB202190 versus vehicle
control. Among the 7 mice in each group, there was a certain
degree of variability in both the basal level of p-MK2, a p38
kinase target that reflects p38 activity, and in the level of inhibi-
tion of MK2 phosphorylation by SB202190. We therefore plotted
nuclear FoxO1 for all 14 mice as a function of p-MK2. The data
show a clear decrease in nuclear FoxO1 in mice as a function
of p38 inhibition, i.e., as indicated by lower p-MK2 (Figure S5D).
Moreover, the p38 inhibitor decreased nuclear GFP-FoxO1 in
HCs treated with glucagon (Figure S5E). These combined data
are consistent with a model in which CaMKII promotes FoxO1
nuclear localization through p38 activation. Whether p38 func-
tions in CaMKII-induced FoxO1 nuclear localization by directly
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Figure 6. The Role of Non-AKT-Phospho Sites of FoxO1 in CaMKII-Mediated FoxO1 Nuclear Localization
(A) HCs fromWT andCamk2g/micewere transducedwith adeno-FLAG-FoxO1 at anMOI of 2. Cells were serum-depleted overnight and then incubated for 5 hr
in serum-free media. FoxO1 was immunopurified using anti-FLAG, followed by reduction, alkylation, and proteolytic digestion. Phosphorylated peptides were
enriched by TiO2 chromatography and then analyzed by LC-MS/MS as described in Experimental Procedures. The table shows spectral count number, Debunker
score, and Ascore of phosphorylated peptides in KO andWT samples;D in the peptide sequence indicates the phosphorylation site. The cutoff values for spectral
count #, Debunker score, and Ascore are set at 5, 0.5, and 12, respectively. The spectra of peptides with scores that are below these values (italics) were checked
manually to eliminate uncertain phosphorylation sites (Figures S4A and S4B forWT peptides 4 and 5; and http://fields.scripps.edu/published/foxo1_Tabas_2012/
for KO peptides 7, 10, and 11). The KO/WT ratio of spectral counts was calculated only for peptides with a combined spectral count in KO and WT >10.
(B) HCs from L-FoxO1 mice were transfected with expression plasmids encoding murine FLAG-FoxO1 or FLAG-7A-FoxO1 mutant. After 48 hr, the cells were
serum-depleted overnight and then incubated with glucagon (100 nm) for 4 hr in serum-free media. Nuclear extracts were assayed by immunoblot for FLAG
and nucleophosmin (nuclear loading control), and RNA from a parallel set of cells was probed for Foxo1 mRNA by RT-qPCR. Densitometric quantification of the
mRNA and immunoblot data are shown in the graph (*p% 0.005; mean ± SEM).
(C) Similar to (B), except the HCs were transduced with adeno-LacZ or CA-CaMKII one day after the transfection with the WT or mutant FoxO1 plasmids
(*p = 0.003; mean ± SEM).
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(Asada et al., 2007) remains to be determined.
The Role of CaMKII in Hepatic Glucose Metabolism
in Obesity
Elevated HGP, in part due to an imbalance of glucagon-to-insulin
signaling, contributes to fasting hyperglycemia in obesity and
other insulin-resistant states (Sørensen et al., 2006; Unger and
Cherrington, 2012; Saltiel, 2001). To test the role of CaMKIIg in
hepatic glucose metabolism in the setting of obesity, we first
sought evidence of hepatic CaMKIIg activation in two mouseCmodels of obesity. We found that the level of p-CaMKII, but
not total CaMKII, was markedly higher in the livers of both
ob/ob mice and WT mice placed on a high-fat, high-calorie
diet for 20 wks (diet-induced obesity [DIO]) (Figure 7A). Antibody
specificity for both anti-p-CaMKII and anti-CaMKII in obese liver
is shown by the absence of the immunoblot bands in obese
Camk2g/ mice. We next tested functional importance by
comparing fasting plasma glucose and hepatic FoxO1-target
gene expression in ob/ob mice transduced with adeno-
KD-CaMKII versus adeno-LacZ control. The mice treated with
adeno-KD-CaMKII had lower fasting glucose, lower bloodell Metabolism 15, 739–751, May 2, 2012 ª2012 Elsevier Inc. 747
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Figure 7. The Role of CaMKII in Hepatic Glucose Metabolism in Obesity
(A) Liver extracts from 10-week-old WT or ob/ob mice, or WT mice fed a chow or high-calorie diet for 20 wks (diet-induced obesity; DIO), were probed for
phospho- and total CaMKIIg and b-actin by immunoblot. Densitometric quantification is shown in the bar graph (***p < 0.001;mean ± SEM). Antibody specificity is
shown by the absence of phospho- and total CaMKIIg bands in liver extracts from DIO Camk2g/ mice.
(B–D) Fasting blood glucose, blood glucose after pyruvate challenge, and liver G6pc, Pck1, and Igfbp1mRNA in ob/obmice after treatment with adeno-LacZ or
KD-CaMKII (n = 5/group; *p < 0.05, **p < 0.01, ***p < 0.005, and ****p < 0.001 versus LacZ; mean ± SEM). See also Figure S7.
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CaMKII in Hepatic Glucose Productionglucose after pyruvate challenge, and lower expression of three
FoxO1-target genes, including G6pc and Pck1 (Figures 7B–7D)
These changes were not associated with either higher plasma
insulin or lower weight in the adeno-KD-CaMKII-treated mice
(data not shown). Thus, hepatic CaMKII is activated in the livers
of obese mice and regulates hepatic glucose metabolism and
FoxO1-target gene expression.
DISCUSSION
The data in this report provide evidence for calcium-mediated
regulation of HGP as part of a pathway that can be summarized
as follows: glucagon/fasting/ cAMP/PKA/ IP3R1/Ca2+I/
CaMKII / nuclear FoxO1 / HGP. CaMKII also mediates
elevated HGP in obese mice (Figure 7), and although more
work is needed in this area, it is possible that the driving force
here is also glucagon (Sørensen et al., 2006; Unger andCherring-
ton, 2012; Saltiel, 2001). As such, the present findings have
implications for three fundamental areas related to HGP: the
molecular mechanisms whereby glucagon and fasting, as well
as obesity/insulin resistance, stimulate HGP; the molecular links
between intracellular calcium and HGP; and the regulation of
FoxO1 nuclear transport. The latter issue is of particular interest,
because while there have been many reports on how insulin/748 Cell Metabolism 15, 739–751, May 2, 2012 ª2012 Elsevier Inc.AKT-mediated phosphorylation of FoxO1, aswell as FoxO1acet-
ylation, promote nuclear exclusion of FoxO1 (Lin andAccili, 2011;
van der Horst and Burgering, 2007), there has been little
emphasis on the regulation of FoxO1 nuclear entry that occurs
in the absence of insulin or in the setting of insulin resistance.
The CaMKII pathway is downstream of cAMP/PKA, and so it
would naturally complement other glucagon-PKA pathways
that stimulate HGP. Thus far, our data suggest that these other
pathways occur in parallel with the CaMKII pathway rather
than also being downstream of CaMKII. For example,
glucagon-PKA directly phosphorylates cAMP response element
binding (CREB) protein, which transcriptionally induces the
FoxO1 transcriptional cofactor PGC1a (Herzig et al., 2001),
but there was no difference in nuclear CREB in livers from
adeno-LacZ versus KD-CaMKII mice (Figure S3B). This was an
important finding, because there are in vitro data in neurons
and in RANKL-treated RAW264.7 cells that CaMKII can acti-
vate/phosphorylate CREB in certain settings (Dash et al., 1991;
Sheng et al., 1991; Ang et al., 2007). We also found that CaMKII
deficiency did not affect nuclear Crtc2 (Figure S3C), which is
another transcriptional activator involved in HGP. These data
indicate that CaMKII in liver works in parallel with these other
pathways, which together effect the nuclear localization of
the proper array of transcriptional factors to mediate HGP. The
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CaMKII in Hepatic Glucose Productioncase with Crtc2 is particularly interesting, because glucagon/
PKA-mediated IP3R activation and ER calcium release promotes
Crtc2 nuclear localization through another calcium-sensing
enzyme, calcineurin (Wang et al., 2012). Indeed, we found that
inhibition of CaMKII and calcineurin are additive in terms of sup-
pressing forskolin-induced G6pc mRNA (unpublished data).
Thus, a common proximal signaling pathway leads to the coor-
dinated nuclear entry of two key HGP transcription factors,
Crtc2 and FoxO1, by different distal mechanisms. In this regard,
it is interesting to note a previous study showing that drugs that
promote calcium entry through the plasma membrane actually
decrease Pck1 mRNA in HCs (Valera et al., 1993), which may
suggest that the route of calcium entry into the cytoplasm is
a factor in determining downstream events.
FoxO1 is phosphorylated at Thr24, Ser253, and Ser316
(murine sequence numbers) by insulin/growth factors via Akt to
promote its nuclear exclusion. It would be counterintuitive to
propose that CaMKII phosphorylates these sites, because
CaMKII promotes FoxO1 nuclear localization, but CaMKII could
theoretically activate a phosphatase that dephosphorylates
these sites. However, CaMKIIg deficiency did not affect the
phosphorylation of these three residues, and it also did not affect
FoxO1 acetylation (Figures S4A and S4B). Instead, we found
evidence that CaMKII mediates the phosphorylation of other
Ser residues on FoxO1, and our Ser-Ala FoxO1 mutant experi-
ments suggest that this action plays a role in CaMKII-mediated
FoxO1 nuclear localization.
The link between CaMKII and FoxO1 phosphorylation may be
direct or indirect. An indirect mechanism, i.e., whereby CaMKII
activates another kinase, could be linked to previous findings
that other kinases can phosphorylate FoxO on non-Akt sites in
a manner that promotes their nuclear retention (Essers et al.,
2004; Chiacchiera and Simone, 2010). Based on the p38 inhibitor
and gene-targeting data herein and the study of Asada et al.
(2007), we suggest that p38 MAPK may also be able to carry
out this function and, indeed, may be the mediator of CaMKII-
induced FoxO1 nuclear localization. In support of this hypothesis
are reports of links between CaMKII and p38 and between p38
and HGP (Cao et al., 2005; Blanquet, 2000). While there is no
direct evidence yet that p38 phosphorylates and thereby acti-
vates FoxO1, the ability of glucocorticoids to promote FoxO1
nuclear localization in rat cardiomyocytes correlated with activa-
tion/phosphorylation of nuclear p38, and immunofluorescence
microscopy and IP/immunoblot data suggested that phospho-
p38 and FoxO1 may interact with each other (Puthanveetil
et al., 2010). Interestingly, there is evidence that FoxO1 may be
able to activate p38 in HCs (Naı¨mi et al., 2007), and so it is
possible that a FoxO1-p38 feed-forward pathway might amplify
the effect the CaMKII-p38 pathway suggested here on FoxO1
nuclear localization. However, more work is needed to establish
the role of p38 and to further elucidate the mechanisms whereby
CaMKII promotes FoxO1 nuclear localization.
The discovery of the role of calcium-CaMKII in HGP not only
provides insight into the physiologic defense against fasting
hypoglycemia but may also reveal therapeutic targets for the
disturbed glucosemetabolism that occurs in the setting of insulin
resistance, as suggested by the data in Figure 7. Indeed, in type
2 diabetes, disproportionate HGP and an imbalance of glucagon
versus insulin signaling contributes to fasting hyperglycemiaC(Sørensen et al., 2006; Saltiel, 2001). Moreover, glucagon
signaling has also been implicated in type 1 diabetes (Unger
and Cherrington, 2012). In this context, future studies will further
address the pathophysiologic role(s) andmechanisms of hepatic
CaMKIIg in obesity, insulin resistance, and diabetes and thereby
evaluate its potential as a therapeutic target in these disorders.
EXPERIMENTAL PROCEDURES
Measurement of CaMKII Activity
CaMKII activity wasassayedusing aCaMKII assay kit fromPromega according
to the manufacturer’s instructions. After the HCs were treated as indicated in
the figure legends, they were lysed by a 5 min exposure to 1% Triton X-100
in 50 mM HEPES, 150 mM NaCl, 10 mM Na pyrophosphate, 10 mM EDTA,
10mMEGTA, 1mMNa3VO4, 50mMNaF, 1mMphenylmethylsulfonyl fluoride,
and 5 mg ml1 leupeptin. Next, [g-32P]ATP and biotinylated CaMKII peptide
substrate were added to the lysate or to the immunoprecipitated complexes
(see below). After incubation for 10 min at 30C, the [32P]-phosphorylated
substrate was separated from the residual [32P]ATP using SAM biotin-capture
membrane and thenquantitated using a scintillation counter. Assayswere con-
ducted with or without calmodulin, and the activity value in the absence of
calmodulin was subtracted from those obtained in the presence of calmodulin.
Glucose Production in Primary HCs
Glucose production assays were carried out as described (Yoon et al., 2001).
Briefly, after primary mouse HCs were harvested and cultured as described
above, the cell culture medium was switched to glucose- and phenol-free
DMEM (pH 7.4) supplemented with 20 mM sodium lactate and 2 mM sodium
pyruvate. After 16 hr of culture, 500 ml medium was collected, and the glucose
contentwasmeasuredusingacolorimetricglucoseassaykit (Abcam).The read-
ings were then normalized to the total protein amount in the whole-cell lysates.
Mouse Experiments
Camk2g/ mice were generated as described previously (Backs et al., 2010)
and crossed onto the C57BL6/J background. ob/ob mice were obtained from
Jackson Labs. Mice were fed a standard chow diet, or a high-fat diet with
60% kcal from fat for the experiments in Figure 7, and maintained on a
12-hr-light-dark cycle. Recombinant adenovirus (1.5 3 109 plaque-forming
unit/mice)wasdeliveredby tail vein injection,andexperimentswerecommenced
after 5 days. Fasting blood glucose was measured in mice that were fasted for
12–14hr,with free access towater, usingaglucosemeter (OneTouchUltra, Life-
scan). Pyruvate-tolerance tests were carried out with an intraperitoneal injection
of 2 g kg1 bodyweight pyruvate after 17 hr of fasting. Blood glucose levelswere
measured over the following 2 hr. Xestospongin C was administered by daily
i.p. injections to mice at a dose of 10 pmol g1 for 4 days. P38afl/fl mice were
generated as described previously (Engel et al., 2005) and generously provided
by Dr. YibinWang, UCLA School of Medicine. Animal studies were performed in
accordance with the Columbia University Animal Research Committee.
Hepatic Glycogen Measurement
Frozen livers (50100mg) were homogenized in 1ml of H2Owith protease and
phosphatase inhibitors. Samples were then mixed with KOH (1:2), boiled for
25 min and washed with 70% ethanol. The pellet was dried and dissolved in
100 ml H2O, and the glycogen content was assessed using the Glycogen Assay
Kit (Abcam) according to the manufacturer’s instructions. Data represent the
mean ± SEM.
PAS Staining of Mouse Liver Sections
Liver samples were fixed in 10% neutral-buffered formalin for 24 hr and
embedded in paraffin. Sections (5 mm) were stained for glycogen using PAS
stain (Sigma) according to manufacturer’s instructions. The sections were
then counterstained with hematoxylin and examined by light microscopy.
For the quantification of PAS staining, five fields from four different sections
were chosen randomly, and the number of PAS-positive cells was counted
and expressed as the percentage of the total number of cells (Hammad
et al., 1982). Two independent investigators, blinded to the identity of the
samples, performed the analysis.ell Metabolism 15, 739–751, May 2, 2012 ª2012 Elsevier Inc. 749
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Protein and phosphopeptide identification, quantification, and phospho anal-
ysis were performed with Integrated Proteomics Pipeline - IP2 (Integrated Pro-
teomics Applications, Inc., San Diego, CA. http://www.integratedproteomics.
com/) using ProLuCID, DTASelect2, Census, DeBunker, and Ascore.
Spectrum raw files were extracted into ms1 and ms2 files (McDonald et al.,
2004) from raw files using RawExtract 1.9.9 (http://fields.scripps.edu/
downloads.php) and the tandem mass spectra were searched against
EBI IPI mouse protein database (http://www.ebi.ac.uk/IPI/IPImouse.html,
released on March 24, 2010). In order to accurately estimate peptide
probabilities and FDRs, we used a decoy database containing the reversed
sequences of all the proteins appended to the target database (Peng et al.,
2003). Tandemmass spectra were matched to sequences using the ProLuCID
(Xu et al., 2006) algorithm with 50 ppm peptide mass tolerance. ProLuCID
searches were done on an Intel Xeon cluster running under the Linux operating
system. The search space included all fully and half-tryptic peptide candidates
that fell within the mass tolerance window. Carbamidomethylation (+57.02146
Da) of cysteine was considered as a static modification, while phosphorylation
(+79.9663) on serine, threonine, and tyrosine were considered as variable
modifications.
The validity of peptide/spectrum matches (PSMs) was assessed in
DTASelect (Tabb et al., 2002; Cociorva et al., 2007) using two SEQUEST
(Eng et al., 1994) defined parameters, the cross-correlation score (XCorr),
and normalized difference in cross-correlation scores (DeltaCN). The search
results were grouped by charge state (+1, +2, +3, and greater than +3) and
tryptic status (fully tryptic, half-tryptic, and nontryptic), resulting in 12 distinct
subgroups. In each one of these subgroups, the distribution of Xcorr, DeltaCN,
and DeltaMass values for (1) direct and (2) decoy database PSMs was ob-
tained, and then the direct and decoy subsets were separated by discriminant
analysis. Full separation of the direct and decoy PSM subsets is not generally
possible; therefore, peptide match probabilities were calculated based on
a nonparametric fit of the direct and decoy score distributions. A peptide
confidence of 99.5% was set as the minimum threshold, and only phospho-
peptides with delta mass less than 10 ppm were accepted. The FDR was
calculated as the percentage of reverse decoy PSMs among all the PSMs
that passed the 99.5% confidence threshold. After this last filtering step, we
estimate that both the protein and peptide FDRs were both below 0.1%. After
database searching and DTASelect2 filtering, phosphopeptides were
analyzed with IP2 phospho analysis tool that uses Ascore (Beausoleil et al.,
2006) and Debunker (Lu et al., 2007). Peptides and phosphopeptides were
quantified using the Spectral Count method (Liu et al., 2004).
Statistical Analysis
All results are presented as mean ± SEM. p values were calculated using the
Student’s t test for normally distributed data and the Mann-Whitney rank
sum test for nonnormally distributed data.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, Supplemental Experimental
Procedures, and two tables and can be found with this article online at
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